1 March 1996 | Volume 124 Issue 5 | Pages 495-496
BRIEF COMMUNICATION
Remission of Polycythemia Vera after Surgical Cure of Acromegaly
Polycythemia can be classified as a secondary or primary disorder. Increased erythropoietin levels associated with decreased oxygen saturation or with release by certain tumors cause secondary polycythemia. Polycythemia vera is a myeloproliferative disease characterized by abnormal clonal proliferation of an early hematopoietic progenitor, which leads to hyperplasia of all myeloid lineage cells [1]. Diagnostic criteria include increased erythrocyte mass associated with either splenomegaly or increased leukocyte and platelet counts. The precise cause of the marked erythroid expansion observed in patients with polycythemia vera has been debated. Recent studies [2-6] have suggested that insulin-like growth factor 1 (IGF-1) may play a role. We recently evaluated a patient who presented with both polycythemia (with in vitro features of polycythemia vera) and acromegaly. Treatment of acromegaly resulted in complete remission of hematologic abnormalities, suggesting a causal relation between growth hormone or IGF-1 and the development of polycythemia.
Case Report
![]()
Top
Case Report
Discussion
Author & Article Info
References
A 42-year-old man who had had splenectomy for spontaneous splenic hematoma in 1976 was first referred to the department of hematology in 1988 for evaluation of polycythemia. His hematologic variables were the following: hemoglobin level, 187 g/L; hematocrit, 0.58; total blood volume, 88 mL/kg body weight (normal value less than 80 mL/kg body weight); erythrocyte mass, 41 mL/kg body weight; and plasma volume, 46 mL/kg body weight. Serum erythropoietin levels (measured by immunoenzyme assay) were barely detectable at 2 U/L (Table 1). The bone marrow aspirate was hypercellular, with a predominance of erythroid and megakaryocytic progenitors. Marrow samples were then tested by using an in vitro colony-forming unit erythroid assay. Under serum and serum-free conditions, marrow cultures showed spontaneous growth of erythroid progenitors in the absence of exogenous erythropoietin. Several features excluded the diagnosis of secondary polycythemia: normal oxygen saturation, no cardiac or hemoglobin abnormalities, no tumor lesions, and no history of smoking. Leukocyte and platelet counts were normal, and polycythemia vera was diagnosed on the basis of spontaneous in vitro growth of erythroid progenitors [7, 8]. The patient then had therapeutic phlebotomies.
|
In 1990, the patient was referred to the department of endocrinology for evaluation of acromegaly. His serum growth hormone (throughout a diurnal hourly profile), serum IGF-1, and urinary growth hormone levels were increased (Table 1). Results of assays for other pituitary hormones were normal. An 8-mm intrasellar pituitary growth hormone-secreting adenoma was surgically removed.
Six months after surgery, serum growth hormone levels, IGF-1 levels, and other pituitary functions were normal, and the hematologic abnormalities had resolved (Table 1). Results of in vitro colony assays no longer showed spontaneous colony growth. After a 4-year follow-up, we have seen no evidence of acromegaly or polycythemia.
Discussion
|
|---|
|
|
|---|
In retrospect, some of the hematologic abnormalities could have been caused by underlying acromegaly. In patients with acromegaly, the hemoglobin level and hematocrit are usually normal and the bone marrow is usually normocellular. We did not observe spontaneous growth of colony-forming unit erythroids in marrow cultures from two patients with active acromegaly (unpublished observations). Although most untreated patients with acromegaly have a normal hematocrit, they also have substantially higher plasma volume, erythrocyte mass, and total blood volume than normal persons; these indices return to normal after treatment [9, 10]. In our patient, the return of these variables to normal may simply reflect the correction of growth hormone levels. After therapy, the hematocrit, erythropoietin level, and in vitro growth of erythroid progenitors also returned to normal, suggesting that growth hormone, IGF-1, or both also induced these abnormalities.
Spontaneous erythroid progenitor growth in vitro is specifically observed with polycythemia vera [7, 8] and is caused, at least in part, by low IGF-1 levels in serum or nondelipidated albumins [11]. Polycythemia vera erythroid progenitors are hypersensitive to low IGF-1 levels compared with normal progenitors [2].
In our patient, the findings suggest that high serum levels of growth hormone, IGF-1, or both may have enhanced the proliferation of an abnormal, hypersensitive progenitor clone to IGF-1. The patient will be followed to determine whether a quiescent, abnormal clone has the potential to recur in the absence of excess hormonal stimulation.
Acknowledgments: The authors thank Drs. Lorian and Helal, who referred the patient to the Department of Endocrinology at the Hopital Bicetre.
Dr. Casadevall: Service d'Hematologie, Hopital Raymond Poincare, 104 Boulevard R. Poincare, F-92380, Garches, France. Dr. Abboud: Department of Medicine/Nephrology, University of Texas Health Science Center, 77 Floyd Curl Drive, San Antonio, TX 78248.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976; 295:913-6.
2. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994; 83:99-112.
3. Claustres M, Chatelain P, Sultan C. Insulin-like growth factor 1 stimulates human erythroid colony formation in vitro. J Clin Endocrinol Metab. 1987; 65:78-82.
4. Kurtz A, Zapf J, Eckardt KU, Clemons G, Froesch ER, Bauer C. Insulin-like growth factor 1 stimulates erythropoiesis in hypophysectomized rats. Proc Natl Acad Sci U S A. 1988; 85:7825-9.
5. Ratajczak MZ, Kuczynsky WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, et al. A reappraisal of the role of insulin-like growth factor 1 in the regulation of human hematopoiesis. J Clin Invest. 1994; 94:320-7.
6. Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor 1, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest. 1994; 94:34-43.
7. Valla D, Casadevall N, Lacombe G, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985; 103:329-34.
8. Lemoine F, Najman A, Baillou C, Stachowiak J, Boffa G, Aegerter P, et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 1986; 68:996-1002.
9. Strauch G, Lego A, Therain F, Bricaire H. Reversible plasma and red blood cell volumes increase in acromegaly. Acta Endocrinol (Copenh). 1977; 85:465-78.
10. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 1990; 113:921-5.
11. Congote LF. Extraction of an erythrotropin-like factor from bovine serum albumin (Cohn fraction V). In Vitro Cell Dev Biol. 1987; 23:361-6.
This article has been cited by other articles:
![]() |
L. Claxton A review of conflict of interest, competing interest, and bias for toxicologists Toxicology and Industrial Health, November 1, 2007; 23(10): 557 - 571. [Abstract] [PDF] |
||||
![]() |
E. Eugster Gigantism J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4379 - 4384. [Full Text] |
||||
![]() |
A. M. Mirza, S. Ezzat, and A. A. Axelrad Insulin-Like Growth Factor Binding Protein-1 Is Elevated in Patients With Polycythemia Vera and Stimulates Erythroid Burst Formation In Vitro Blood, March 15, 1997; 89(6): 1862 - 1869. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||